Featured Research

from universities, journals, and other organizations

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

Date:
April 7, 2014
Source:
Institute for Quality and Efficiency in Health Care
Summary:
A Rilpivirine combination product in HIV-1 patients with previous antiretroviral treatment was not shown to demonstrate any added benefit in a recent study. The only study cited in the dossier was too short for the assessment of an added benefit, and the appropriate comparator therapy was not implemented.

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment. For men, the Institute then found proof, and for women, indications of a considerable added benefit of the fixed combination in comparison with the appropriate comparator therapy.

In the end of 2013, the approval was expanded to people with previous antiretroviral treatment, and the drug manufacturer submitted a dossier for this new therapeutic indication, in which it claimed an added benefit again. IQWiG came to a different conclusion: The only study cited in the dossier was too short for the assessment of an added benefit, and the appropriate comparator therapy was not implemented. Hence an added benefit of rilpivirine/emtricitabine/tenofovir in the treatment of adults infected with HIV-1 with previous antiretroviral treatment is not proven.

New therapeutic indication, new comparator therapy

According to the expansion of approval from November 2013, the fixed drug combination can now also be used in HIV-1 infected adults with a viral load of no more than 100,000 RNA copies per millilitre who have already received antiretroviral treatment -- provided that their virus has no mutations associated with known resistance to the drugs.

Since these patients had already received antiretroviral treatment, which possibly did not have a satisfactory effect or had to be discontinued, the Federal Joint Committee (G-BA) specified a different appropriate comparator therapy than in 2012 for non-pretreated patients: Antiretroviral treatment was now to be specified individually, depending on the previous treatment and the reason for treatment switching, e.g. treatment failure or side effects.

Comparator therapy not implemented

In its dossier, the manufacturer presented one single study, in which the drug combination was compared with an individual antiretroviral treatment. However, no switch of treatment was possible in the control group. Instead, the patients continued their previous treatment -- although approximately 10% of them complained of side effects in the beginning, and about 20% claimed to be worried about longterm side effects of their previous treatment.

Randomized controlled phase far too short

Moreover, the rilpivirine/emtricitabine/tenofovir combination was only compared with the appropriate comparator therapy for 24 weeks in the study. But the research question of the benefit assessment cannot be answered on the basis of such a short study; this would require at least one to two years.

For these reasons, an added benefit of rilpivirine/emtricitabine/tenofovir is not proven for HIV-1 infected adults with previous antiretroviral treatment whose viruses do not have mutations associated with resistance.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven." ScienceDaily. ScienceDaily, 7 April 2014. <www.sciencedaily.com/releases/2014/04/140407101720.htm>.
Institute for Quality and Efficiency in Health Care. (2014, April 7). Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2014/04/140407101720.htm
Institute for Quality and Efficiency in Health Care. "Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven." ScienceDaily. www.sciencedaily.com/releases/2014/04/140407101720.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins